Richard Lingard

Media

Press & Commentary

Expert perspective on Dotmatics, scientific informatics, the commercial realities of research software, AI-ready data and the changing needs of drug discovery teams.

Available commentary

Topics Richard can address with first-hand authority

These are commentary themes and interview subjects, not claimed published articles.

01

Commentary

Why Scientific Informatics Is the Backbone of Modern Drug Discovery

Media enquiry ↗
02

Commentary

How AI-Driven Data Infrastructure Is Reshaping the Life Sciences Sector

Media enquiry ↗
03

Commentary

The Case for Treating Scientific Data as a Strategic Asset

Media enquiry ↗
04

Commentary

What 30 Years in Scientific Informatics Taught Me About Building Durable Platforms

Media enquiry ↗
05

Commentary

How Cheminformatics and Bioinformatics Are Converging in Drug Discovery

Media enquiry ↗
06

Commentary

Why Most Drug Discovery Data Platforms Fail Before They Scale

Media enquiry ↗
07

Commentary

The Commercial Leader’s Guide to Expanding Life Sciences Technology Globally

Media enquiry ↗
08

Commentary

How to Build and Lead Global Commercial Operations in a Niche Scientific Market

Media enquiry ↗
09

Commentary

What Genomics Taught Me About the Limits of Early-Stage Data Infrastructure

Media enquiry ↗

Why Richard

A source who knows the platform, the customer and the market.

Inside Dotmatics

Led global commercial operations during a defining growth period and understands how scientific platforms earn adoption.

Across discovery

Three decades spanning molecular modelling, genomics, cheminformatics, research information and life sciences software.

Looking forward

Founded Adroit AI to address the connected scientific data and deployment requirements emerging now.

Available for expert comment, interviews, podcasts and contributed articles.

Contact Richard